• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Insmed to defer Phase 3 study of Arikace in US

According to Insmed, the company has decided to focus on European and Canadian studies of its Arikace liposomal amikacin for inhalation and to put a US Phase 3 study on the back burner. The CLEAR-108 (CLinical Evaluation of ARikace) Phase 3 study of Arikace for the treatment of patients with cystic fibrosis is already underway in Europe and Canada, and Insmed says that it will wait for top-line results from that study before proceeding with Arikace for CF in the US. The FDA lifted a clinical hold on Arikace for CF at the beginning of May 2012.

Insmed President and CEO Timothy Whitten explained, “Insmed has determined that its current resources will be applied towards the CLEAR-108 phase 3 European and Canadian registrational study of Arikace in patients with Cystic Fibrosis (CF)-related Pseudomonas aeruginosa lung infections, the TARGET-NTM phase 2 trial of Arikace in patients with non-tuberculous mycobacteria (NTM) lung disease and the 9-month dog toxicity study.”

He added, “We believe this Arikace development program prioritizes the most compelling near-term opportunities for Insmed and its shareholders. The CLEAR-108 trial provides Insmed with the earliest opportunity to garner critical phase 3 Arikace data in a broad cystic fibrosis patient population while generating important information on the efficacy and safety of Arikace as compared to the current standard of care. In NTM, Arikace has the opportunity to become a part of standard therapy for a rapidly growing chronic disease that has a high unmet medical need with limited treatment options. We project our current cash position to be sufficient to generate top-line data from the three prioritized Arikace studies.”

The company expects to get top-line data from the CLEAR-108 study by mid-2013 and says that it plans to enroll patients in the Phase 2 TARGET-NTM (Treatment with ARikace to Realize Greater Efficacy Trial) trial by mid-2012.

Read the Insmed press release.

Share

published on May 30, 2012

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews